

(19)



(11) Patent Number: KE 909

(45) Date of grant: 20/12/2021

(12) PATENT

(51) Int.Cl.2016.01: A 61K 31/00

(21) Application Number:
KE/P/2017/2613

(22) Filing Date:
06/03/2017

(73) Owner:

JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY(JKUAT) of P.O. BOX 62000-00200, NAIROBI, Kenya

(72) Inventors:

JOSEPH K. NG'ANG'A, P.O. BOX 62000-00200 NAIROBI, Kenya; FRANCIS KIMANI, P.O. BOX 43640-00100 NAIROBI, Kenya; PETER KIRIRA, P.O. BOX 67829-00200 NAIROBI, Kenya; JOHNSON KINYUA, P.O. BOX 62000-00200 NAIROBI, Kenya; FLORENCE NGONGA, P.O. BOX 62000-00200 NAIROBI, Kenya; LUCY KANGETHE, P.O. BOX 62000-00200 NAIROBI, Kenya; JOSEPH NJOKA, P.O. BOX 67829-00200 NAIROBI, Kenya; MILKA WAMBUI, P. O. BOPX 62000-00200 NAIROBI, Kenya and MARTIN SIFUNA, P.O. BOX 67829-00200 NAIROBI, Kenya

(74) Agent/address for correspondence:

DIRECTORATE OF INTELLECTUAL PROPERTY
MANAGEMENT AND UNIVERSITY- INDUSTRY LIAISON,
JKUAT
P.O BOX 62000-00200, NAIROBI

(54) Title:

ANTIMALARIAL COMPOSITION COMPRISING 3-CHLORO-4-(4-CHLOROPHOXY) ANILINE

(57) Abstract:

An antimalarial composition comprising 3-chloro-4-(4-chlorophenoxy) aniline is disclosed. The present invention concerns the effectiveness of 3-chloro-4-(4-chlorophenoxy) aniline (ANI) of structural Formula (A) below against both CQ-sensitive (30₇) and CQ-resistant (W₂) Plasmodium falciparum isolates in vitro and against Plasmodium berghei in mice. The drug's IC₅₀ concentration is determined by culturing the parasite in media containing radiolabeled hypoxanthine while determination of chemo suppression of drug combinations are based on Peters' 4-day test in P. berghei infected Swiss albino mice using Giemsa-stained thin tail blood smears. It teaches that in the in vitro test, 3-chloro-4-(4-chlorophenoxy) aniline has an IC₅₀ value of 8.hlg/ml against the chloroquine resistant strain (W₂) and an IC₅₀ value of 7.1ug/ml against choloquine sensitive (3D7). It reveals that the 50% inhibitory concentration of 3-chloro-4-(4- chlorophenoxy) aniline in the Swiss albino mice is 4.18mg/kg thus demonstrating an increased effectiveness over individual drugs portending effective antimalarial drug partnership.